#USA #Kessler Topaz #Radnor #NV #uniQure

Kessler Topaz Meltzer & Check, LLP Investigates uniQure N.V. (NASDAQ: QURE)

Kessler Topaz Meltzer & Check, LLP, a prominent law firm specializing in securities fraud class actions, is currently conducting an investigation aimed at uncovering potential violations of federal securities laws related to uniQure N.V. (NASDAQ: QURE). This investigation has been prompted by alarming events surrounding the company’s investigational gene therapy, AMT-130, which is designed to treat Huntington's disease.

On November 3, 2025, uniQure issued a troubling press release informing investors that the FDA had communicated concerns regarding their data supporting a Biologics License Application (BLA) for AMT-130. The announcement revealed that the FDA no longer believes the data obtained from Phase I/II studies adequately substantiates the BLA submission. Consequently, uniQure expressed uncertainty about the timing of this critical submission, raising significant concerns among investors about the drug's future.

The negative news had an immediate impact on the company's stock price, which plummeted over 50% in a matter of days. The share price fell from a closing rate of $67.69 on October 31 to a stark $34.29 by the end of trading on November 3. This drastic decline indicates serious investor apprehension and has stressed the necessity for an investigation into whether uniQure misled its investors regarding the viability of its drug candidate.

Kessler Topaz Meltzer & Check invites uniQure investors, particularly those who incurred significant financial losses as a result of the stock's sharp decline, to participate in the investigation. Investors can fill out an online form provided by the firm or reach out to them directly via phone or email to discuss their situations.

The law firm's reputation speaks for itself as it has a consistent track record of representing both individual and institutional investors in various securities litigations. Its prestigious accolades and recognition within the legal community further emphasize its commitment to seeking justice for clients. With offices located in Pennsylvania and California, Kessler Topaz aims to protect the rights of investors and hold companies accountable for potential fraud and securities violations.

For uniQure investors concerned about the implications of these developments, timely action is crucial. Potential legal recourse may help mitigate losses suffered during this tumultuous period for the company. Kessler Topaz is prepared to guide investors through this process, ensuring they understand their rights and the necessary steps that can be taken.

To learn more about the ongoing investigation into uniQure and to check if you qualify for participation, interested parties should not hesitate to reach out to Kessler Topaz Meltzer & Check for additional information. The firm is properly positioned to navigate the complex landscape of securities fraud, and their expertise may be invaluable to those affected by uniQure’s sudden market shifts.

In conclusion, the situation surrounding uniQure N.V. serves as a critical reminder of the volatile nature of the biotech industry. Investors are urged to stay informed and take proactive measures to protect their interests as this investigation unfolds. Kessler Topaz Meltzer & Check is on hand to assist all impacted parties through this challenging period.